Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Current clinical use of biomarkers for epithelial ovarian cancer.

Authors:
Richard G Moore Shannon Maclaughlan

Curr Opin Oncol 2010 Sep;22(5):492-7

Department of Obstetrics and Gynecology, Women and Infants' Hospital, Brown University, Providence, RI 02905, USA.

Purpose Of Review: The majority of women diagnosed with epithelial ovarian cancer (EOC) will be diagnosed with advanced stage disease, a stage that is fundamentally incurable. Survival rates for this deadly disease have improved over the last 25 years secondarily to the advances in surgery and chemotherapeutics. Effective screening protocols are not currently available, and risk assessment protocols for the presence of EOC in women with an ovarian cyst need improvement. Earlier diagnosis may result in stage migration and decreased morbidity for women diagnosed with EOC. Better risk assessment will allow the triage of women to centers of excellence in the treatment and management of ovarian cancer with improved outcomes and survival rates. This review will focus on new biomarkers and algorithms for screening and risk assessment for ovarian cancer.

Recent Findings: The use of multiple biomarkers and statistical algorithms has been shown to be an accurate method for assessing the risk of ovarian cancer in women with ovarian cysts/masses preoperatively. Newer algorithms employing biomarkers to trigger ultrasound imaging for screening also show promise. The addition of novel biomarkers such as human epididymis protein 4 to the use of CA125 improves the sensitivity and specificity over that of either biomarker alone for the management of EOC.

Summary: For more than 25 years CA125 has been the main biomarker for the management of women with EOC. Recently, novel biomarkers have become available clinically that improve upon the use of CA125 for the risk assessment and management of women with ovarian cancer.

Download full-text PDF

 Source
http://dx.doi.org/10.1097/CCO.0b013e32833c3351DOI Listing
September 2010

Publication Analysis

Top Keywords

ovarian cancer
20
risk assessment
16
women ovarian
12
management women
8
novel biomarkers
8
biomarker management
8
women diagnosed
8
survival rates
8
epithelial ovarian
8
ovarian
8
women
7
biomarkers
6
cancer
5
risk
5
focus biomarkers
4
review will
4
rates review
4
statistical algorithms
4
algorithms accurate
4
will focus
4

Keyword Occurance

Similar Publications

DNA damage response and PD-1/PD-L1 pathway in ovarian cancer.

Authors:
Tianyu Zhang Shuangshuang Zheng Yang Liu Xiao Li Jing Wu Yue Sun Guoyan Liu

DNA Repair (Amst) 2021 Apr 1;102:103112. Epub 2021 Apr 1.

Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, No. 154 Anshan Road, Tianjin, 300052, China; Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin, 300052, China. Electronic address:

Ovarian cancer has a poor prognosis due to drug resistance, relapse and metastasis. In recent years, immunotherapy has been applied in numerous cancers clinically. However, the effect of immunotherapy monotherapy in ovarian cancer is limited. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Female fertility preservation: Impact of cancer on ovarian function and oocyte quality.

Authors:
Cristina Fabiani Maria Giulia Ferrante Caterina Meneghini Emanuele Licata Gemma Paciotti Mariagrazia Gallo Michele Schiavi Vincenzo Spina Antonella Guarino Donatella Caserta Rocco Rago

Int J Gynaecol Obstet 2021 Apr 10. Epub 2021 Apr 10.

Physiopathology of Reproduction and Andrology Unit, Sandro Pertini Hospital, Rome, Italy.

Objective: To evaluate the influence of cancer on ovarian response and oocyte quality in controlled ovarian hyperstimulation (COH).

Methods: This prospective study conducted at the Physiopathology of Reproduction and Andrology Unit of Sandro Pertini Hospital enrolled 82 cancer patients undergoing controlled ovarian stimulation (COH) cycles for fertility preservation, and age- and date-matched controls undergoing COH for in vitro fertilization (IVF) for male-factor infertility from June 2016 to November 2019. The interventions performed were COH, oocyte retrieval, and quality evaluation. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Aggressive anaplastic ovarian carcinoma in a young nulliparous patient.

Authors:
Alicia Hunter Susan Addley Hooman Soleymani Majd

BMJ Case Rep 2021 Apr 9;14(4). Epub 2021 Apr 9.

Department of Gynaecology Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK

Ovarian tumours harbouring foci of anaplastic carcinoma are extremely rare. With just a handful of cases reported in the literature, understanding of the disease and optimal management remains limited. A 38-year-old woman was referred to the gynaeoncologists with a multiloculated complex ovarian mass. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.

Authors:
Bettina Meiser Rajneesh Kaur April Morrow Michelle Peate W K Tim Wong Emily McPike Elisa Cops Cassandra Nichols Rachel Austin Miriam Fine Letitia Thrupp Robyn Ward Finlay Macrae Janet E Hiller Alison H Trainer Gillian Mitchell

Hered Cancer Clin Pract 2021 Apr 9;19(1):24. Epub 2021 Apr 9.

Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.

Background: This nationwide study assessed the impact of nationally agreed cancer genetics guidelines on use of BRCA1/2 germline testing, risk management advice given by health professionals to women with pathogenic BRCA1/2 variants and uptake of such advice by patients.

Methods: Clinic files of 883 women who had initial proband screens for BRCA1/2 pathogenic variants at 12 familial cancer clinics between July 2008-July 2009 (i.e. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Effect of resveratrol on mouse ovarian vitrification and transplantation.

Authors:
Dalin Wang Menghui Geng Dongying Gan Gege Han Gao Gao Aying Xing Yugui Cui Yanqiu Hu

Reprod Biol Endocrinol 2021 Apr 9;19(1):54. Epub 2021 Apr 9.

State Key Laboratory of Reproductive Medicine, Clinical Center of Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University, Nanjing, 210029, Jiangsu Province, China.

Background: After ovarian tissue transplantation, ischemia-reperfusion injury and free radicals cause follicle depletion and apoptosis. Therefore, the use of antioxidants to reduce the production of free radicals is an important method to address the consequences of ischemia-reperfusion injury. Resveratrol is a natural active polyphenol compound with anti-inflammatory, antitumor, strong antioxidant and anti-free radical properties. Read More

View Article and Full-Text PDF
April 2021
Similar Publications